Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Conditions
Brief summary
The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma. This study is for patients who have angiosarcoma that has gotten worse after they received chemotherapy. Regorafenib is a type of drug called a kinase inhibitor. Regorafenib interferes with how some kinase proteins work. Some of these kinases in cancer cells might normally help the cancer cells grow or form new blood vessels that could feed a growing tumor. By blocking these proteins, regorafenib may help stop the growth of certain cancers.
Detailed description
PRIMARY OBJECTIVES: I. To define the progression-free survival (PFS) at 4 months with daily oral regorafenib (160 mg) in previously treated locally advanced/metastatic angiosarcoma patients SECONDARY OBJECTIVES: I. Progression-free rate at 3 and 6 months. II. Progression-free survival. III. Overall survival (up to 5 years). IV. Response rate (by Response Evaluation Criteria in Solid Tumors \[RECIST\] version \[v\] 1.1). V. Rate and duration of tumor control (complete response \[CR\] + partial response \[PR\] + stable disease \[SD\]). VI. Safety/tolerability of regorafenib. OUTLINE: Patients receive regorafenib orally (PO) once daily (QD) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for up to 5 years.
Interventions
DRUGregorafenib
Given PO
Sponsors
Bayer
National Cancer Institute (NCI)
Northwestern University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Life expectancy of at least 4 months * Histologically confirmed angiosarcoma * Tumor deemed unresectable or metastatic * Measurable disease per RECIST v 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 * Progressive disease under last palliative therapy with a history of prior ifosfamide, doxorubicin or taxane therapy for angiosarcoma; up to 4 prior therapies are allowed * All acute toxic effects of any prior treatment have resolved to grade 1 or less (by National Cancer Institute-Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] v 4.0) at the time of registration; NOTE: Exceptions to this criterion will include alopecia and fatigue * Total bilirubin =\< 1.5 x the upper limits of normal (ULN) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 2.5 x ULN (=\< 5 x ULN for subjects with liver involvement of their cancer) * Alkaline phosphatase limit =\< 2.5 x ULN (=\< 5 x ULN for subjects with liver involvement of their cancer) * Lipase =\< 1.5 x the ULN * Serum creatinine =\< 1.5 x the ULN * International normalized ratio (INR)/partial thromboplastin time (PTT) \< 1.5 x ULN * Platelet count \> 100000/mm\^3 * Hemoglobin \> 9 g/dL * Absolute neutrophil count \> 1500/mm\^3 * If baseline urine protein creatinine (UPC) \>= 1, a 24-hour urine protein must be assessed; patients must have a 24-hour urine protein value \< grade 3 (\> 3.5 g/24 hours) to be eligible * NOTE: Blood transfusion to meet the above criteria will not be allowed; NOTE: Patients who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care * Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as age \>= 50 years and no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test * Subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at registration until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator * Subject must be able to swallow and retain oral medication * Subjects must be able to understand and be willing to sign the written informed consent form; a signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure
Exclusion criteria
* Uncontrolled hypertension (systolic pressure \> 140 mmHg or diastolic pressure \> 90 mmHg on repeated measurement) despite optimal medical management * Active or clinically significant cardiac disease including: * Congestive heart failure - New York Heart Association \> class II * Active coronary artery disease * Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin * Unstable angina (anginal symptoms at rest), new-onset angina within 3 months before registration, or myocardial infarction within 6 months before registration * Evidence or history of bleeding diathesis or coagulopathy * Any hemorrhage or bleeding event grade 3 within 4 weeks prior to registration * Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of informed consent * Subjects with any previously untreated or concurrent cancer unrelated to angiosarcoma; NOTE: Exceptions include cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before registration are allowed; all treatments must have been completed at least 3 years prior to registration * Patients with pheochromocytoma * Patients with severe hepatic impairment (Child-Pugh class C) * Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy * Ongoing infection \> grade 2 * Evidence of significant central nervous system disease including seizure disorder requiring medication, symptomatic metastatic brain or meningeal tumors * Presence of a non-healing wound, non-healing ulcer, or bone fracture * Renal failure requiring hemo-or peritoneal dialysis * Dehydration \> grade 1 * Interstitial lung disease with ongoing signs and symptoms at the time of registration * Pleural effusion or ascites that causes respiratory compromise (\>= grade 2 dyspnea) * History of organ allograft (including corneal transplant) * Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial * Any malabsorption condition * Evidence of abdominal fistula, gastrointestinal (GI) perforation or intraabdominal abscess * Women who are pregnant or breast-feeding * Concurrent anti-cancer therapy (chemotherapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib) * Prior use of regorafenib * Prior use of sorafenib * Use of cytotoxic chemotherapy within 21 days of registration * Use of targeted therapy within two half-lives of registration * Radiation directed at target lesion within 28 days of registration * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before registration * Therapeutic anticoagulation with Vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids; NOTE: Prophylactic anticoagulation as described below is allowed: * Low dose warfarin (1 mg orally, once daily) with prothrombin time (PT)-international normalized ratio (INR) =\< 1.5 x ULN is permitted; infrequent bleeding or elevations in PT-INR have been reported in some subjects taking warfarin while on regorafenib therapy; therefore, subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes * Low dose aspirin (=\< 100 mg daily) * Prophylactic doses of heparin * Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation * Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) at 4 Months | At 4 months (of treatment) | The progression-free survival (PFS) at 4 months will be defined as the number of patients with progression absent at 4 months divided by the total number of evaluable study patients. This will be measured from start of treatment until time of progression or death, whichever occurs first and will be estimated using Kaplan-Meier methods and reported as a survival probability. Progression will be evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in RECIST v 1.1. Progression will be defined as: Progressive disease (PD): \> 20% increase in the sum diameters of target lesions, taking as reference the smallest sum diameters while on study. The sum diameters must also demonstrate an absolute increase of 5 mm. The appearance of one or more new lesions also qualifies as PD. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Median Progression-free Survival (PFS) | The duration of time from start of treatment until time of progression, up to 5 years | The median progression-free rate (PFR) will be defined as the number of patients with progression absent divided by the total number of evaluable study patients. This will be measured from start of treatment until time of progression or death, whichever occurs first for up to 5 years and will be estimated using Kaplan-Meier methods. Progression will be evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in RECIST v 1.1. Progression will be defined as: Progressive disease (PD): \> 20% increase in the sum diameters of target lesions, taking as reference the smallest sum diameters while on study. The sum diameters must also demonstrate an absolute increase of 5 mm. The appearance of one or more new lesions also qualifies as PD. |
| Overall Survival | From start of treatment up to 5 years | Overall survival will be defined as the time from start of treatment until death from any cause and will be estimated using Kaplan-Meier methods and reported as a survival probability. Patients that are alive at the time of data analysis will be censored at the date of known survival status. |
| Progression-Free Survival (PFS) at 3 and 6 Months | Assessed at 3 months and 6 months | The progression-free survival (PFS) at 3 and 6 months will be defined as the number of patients with progression absent at 3 months and 6 months divided by the total number of evaluable study patients. This will be measured from start of treatment until time of progression or death, whichever occurs first and will be estimated using Kaplan-Meier methods and reported as a survival probability. Progression will be evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in RECIST v 1.1. Progression will be defined as: Progressive disease (PD): \> 20% increase in the sum diameters of target lesions, taking as reference the smallest sum diameters while on study. The sum diameters must also demonstrate an absolute increase of 5 mm. The appearance of one or more new lesions also qualifies as PD. |
| Rate of Tumor Control | At baseline and after every 2 cycles, up to 12 cycles where one cycle is 28 days | Imaging will be used at baseline then after every 2 cycles while on treatment to measure tumor size and response to treatment, the data collected from all patients on study will be used to calculate the rate and duration of tumor control. Response will be evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in RECIST v 1.1. Response and stable disease will be defined as the following: Complete response (CR): Disappearance of all target lesions Partial response (PR): \> 30% decrease in the baseline sum diameters of target lesions Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study |
| Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | From treatment initiation though 30 days post the last treatment for a max of 12 cycles where one cycle is 28 days | Overall worst grade related toxicity (number of patients) was collected from the start of treatment until 30 days post the last treatment where patients were treated until progressive disease or unacceptable toxicity or patient withdrawal of treatment. All Adverse events that were determined to be at least possibly related to treatment are reported. All adverse events will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The severity of an AE is graded as follows: Mild (grade 1): the event causes discomfort without disruption of normal daily activities. Moderate (grade 2): the event causes discomfort that affects normal daily activities. Severe (grade 3): the event makes the patient unable to perform normal daily activities or significantly affects his/her clinical status. Life-threatening (grade 4): the patient was at risk of death at the time of the event. Fatal (grade 5): the event caused death |
| Response Rate | At baseline and after every 2 cycles, up to 12 cycles where one cycle is 28 days | Imaging (such as a CT scan) will be done at baseline (within 4 weeks before the first dose) then after every 2 cycles while on treatment for tumor response evaluation. Response will be evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in RECIST v 1.1. Best response of each patient will be used and responses will be defined as the following: Complete response (CR): Disappearance of all target lesions Partial response (PR): \> 30% decrease in the baseline sum diameters of target lesions |
Countries
United States
Participant flow
Recruitment details
The study was opened for enrollment March 12, 2014 with the first patient starting treatment June 13, 2014. A total of 31 patients were treated under the protocol. The study was permanently suspended to further enrollment August 5, 2019.
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Regorafenib) Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
regorafenib: Given PO | 31 |
| Total | 31 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| 2 Cycles of Treatment | Adverse Event | 2 |
| 2 Cycles of Treatment | Progressive Disease | 2 |
| 2 Cycles of Treatment | Withdrawal by Subject | 4 |
| Follow up 5 Years or Cut of Timepoint | Death | 24 |
| Follow up 5 Years or Cut of Timepoint | Withdrawal by Subject | 3 |
| Reached 1st Response/Continued Treatment | Progressive Disease | 10 |
Baseline characteristics
| Characteristic | Treatment (Regorafenib) |
|---|---|
| Age, Customized | 64.32 years STANDARD_DEVIATION 14.58 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 31 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 27 Participants |
| Region of Enrollment United States | 31 participants |
| Sex: Female, Male Female | 16 Participants |
| Sex: Female, Male Male | 15 Participants |
| Type of disease Locally advanced/Unresectable | 9 Participants |
| Type of disease Metastatic | 21 Participants |
| Type of disease Not reported | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 24 / 31 |
| other Total, other adverse events | 31 / 31 |
| serious Total, serious adverse events | 15 / 31 |
Outcome results
Primary
Progression-Free Survival (PFS) at 4 Months
The progression-free survival (PFS) at 4 months will be defined as the number of patients with progression absent at 4 months divided by the total number of evaluable study patients. This will be measured from start of treatment until time of progression or death, whichever occurs first and will be estimated using Kaplan-Meier methods and reported as a survival probability. Progression will be evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in RECIST v 1.1. Progression will be defined as: Progressive disease (PD): \> 20% increase in the sum diameters of target lesions, taking as reference the smallest sum diameters while on study. The sum diameters must also demonstrate an absolute increase of 5 mm. The appearance of one or more new lesions also qualifies as PD.
Time frame: At 4 months (of treatment)
Population: 8 Patients were not included due to the following reasons: progressive disease, patient refused further treatment (withdrawal of consent for further treatment), toxicity. This was due to data having either missing time points or cycle 1 or Cycle 1: follow up missing from the dataset at the time of the analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Regorafenib) | Progression-Free Survival (PFS) at 4 Months | 52.17 percentage of patients alive |
Secondary
Median Progression-free Survival (PFS)
The median progression-free rate (PFR) will be defined as the number of patients with progression absent divided by the total number of evaluable study patients. This will be measured from start of treatment until time of progression or death, whichever occurs first for up to 5 years and will be estimated using Kaplan-Meier methods. Progression will be evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in RECIST v 1.1. Progression will be defined as: Progressive disease (PD): \> 20% increase in the sum diameters of target lesions, taking as reference the smallest sum diameters while on study. The sum diameters must also demonstrate an absolute increase of 5 mm. The appearance of one or more new lesions also qualifies as PD.
Time frame: The duration of time from start of treatment until time of progression, up to 5 years
Population: 8 Patients were not included due to the following reasons: progressive disease, patient refused further treatment (withdrawal of consent for further treatment), toxicity. This was due to data having either missing time points or cycle 1 or Cycle 1: follow up missing from the dataset at the time of the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Regorafenib) | Median Progression-free Survival (PFS) | 5.49 months |
Secondary
Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0)
Overall worst grade related toxicity (number of patients) was collected from the start of treatment until 30 days post the last treatment where patients were treated until progressive disease or unacceptable toxicity or patient withdrawal of treatment. All Adverse events that were determined to be at least possibly related to treatment are reported. All adverse events will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The severity of an AE is graded as follows: Mild (grade 1): the event causes discomfort without disruption of normal daily activities. Moderate (grade 2): the event causes discomfort that affects normal daily activities. Severe (grade 3): the event makes the patient unable to perform normal daily activities or significantly affects his/her clinical status. Life-threatening (grade 4): the patient was at risk of death at the time of the event. Fatal (grade 5): the event caused death
Time frame: From treatment initiation though 30 days post the last treatment for a max of 12 cycles where one cycle is 28 days
Population: At the time of data pull (12/02/2019) for this outcome measure two patients remained on treatment. Any subsequent AEs determined to be related to treatment for these patients is not included here.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Endocrine disorders | Grade 3 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Nervous system disorders | Grade 2 | 2 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Nervous system disorders | Grade 3 | 1 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Nervous system disorders | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Nervous system disorders | Number of patients who didn't experience any grade | 17 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Psychiatric disorders | Grade 1 | 3 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Psychiatric disorders | Grade 2 | 1 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Psychiatric disorders | Grade 3 | 2 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Psychiatric disorders | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Psychiatric disorders | Number of patients who didn't experience any grade | 25 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Renal and urinary disorders | Grade 1 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Renal and urinary disorders | Grade 2 | 1 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Renal and urinary disorders | Grade 3 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Renal and urinary disorders | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Renal and urinary disorders | Number of patients who didn't experience any grade | 30 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Respiratory, thoracic and mediastinal disorders | Grade 1 | 9 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Respiratory, thoracic and mediastinal disorders | Grade 2 | 1 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Respiratory, thoracic and mediastinal disorders | Grade 3 | 1 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Respiratory, thoracic and mediastinal disorders | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Respiratory, thoracic and mediastinal disorders | Number of patients who didn't experience any grade | 20 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Skin and subcutaneous tissue disorders | Grade 1 | 14 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Skin and subcutaneous tissue disorders | Grade 2 | 6 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Skin and subcutaneous tissue disorders | Grade 3 | 1 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Skin and subcutaneous tissue disorders | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Skin and subcutaneous tissue disorders | Number of patients who didn't experience any grade | 10 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Vascular disorders | Grade 1 | 3 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Vascular disorders | Grade 2 | 8 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Vascular disorders | Grade 3 | 4 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Vascular disorders | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Vascular disorders | Number of patients who didn't experience any grade | 16 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Blood and lymphatic system disorders | Grade 1 | 5 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Blood and lymphatic system disorders | Grade 2 | 3 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Blood and lymphatic system disorders | Grade 3 | 3 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Blood and lymphatic system disorders | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Blood and lymphatic system disorders | Number of patients who didn't experience any grade | 20 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Endocrine disorders | Grade 1 | 1 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Endocrine disorders | Grade 2 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Endocrine disorders | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Endocrine disorders | Number of patients who didn't experience any grade | 30 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Eye disorders | Grade 1 | 2 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Eye disorders | Grade 2 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Eye disorders | Grade 3 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Eye disorders | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Eye disorders | Number of patients who didn't experience any grade | 29 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Gastrointestinal disorders | Grade 1 | 14 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Gastrointestinal disorders | Grade 2 | 9 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Gastrointestinal disorders | Grade 3 | 3 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Gastrointestinal disorders | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Gastrointestinal disorders | Number of patients who didn't experience any grade | 5 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | General disorders | Grade 1 | 11 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | General disorders | Grade 2 | 8 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | General disorders | Grade 3 | 4 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | General disorders | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | General disorders | Number of patients who didn't experience any grade | 8 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Infections and infestations | Grade 1 | 1 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Infections and infestations | Grade 2 | 2 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Infections and infestations | Grade 3 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Infections and infestations | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Infections and infestations | Number of patients who didn't experience any grade | 28 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Injury, poisoning and procedural complications | Grade 1 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Injury, poisoning and procedural complications | Grade 2 | 1 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Injury, poisoning and procedural complications | Grade 3 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Injury, poisoning and procedural complications | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Injury, poisoning and procedural complications | Number of patients who didn't experience any grade | 30 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Metabolism and nutrition disorders | Grade 1 | 10 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Metabolism and nutrition disorders | Grade 2 | 4 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Metabolism and nutrition disorders | Grade 3 | 5 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Metabolism and nutrition disorders | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Metabolism and nutrition disorders | Number of patients who didn't experience any grade | 12 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Investigations | Grade 1 | 14 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Investigations | Grade 2 | 2 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Investigations | Grade 3 | 3 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Investigations | Grade 4 | 1 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Investigations | Number of patients who didn't experience any grade | 11 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | musculoskeletal and connective tissue disorders | Grade 1 | 7 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | musculoskeletal and connective tissue disorders | Grade 2 | 3 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | musculoskeletal and connective tissue disorders | Grade 3 | 1 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | musculoskeletal and connective tissue disorders | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | musculoskeletal and connective tissue disorders | Number of patients who didn't experience any grade | 20 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Neoplasms benign, malignant and unspecified | Grade 1 | 1 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Neoplasms benign, malignant and unspecified | Grade 2 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Neoplasms benign, malignant and unspecified | Grade 3 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Neoplasms benign, malignant and unspecified | Grade 4 | 0 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Neoplasms benign, malignant and unspecified | Number of patients who didn't experience any grade | 30 Participants |
| Treatment (Regorafenib) | Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Nervous system disorders | Grade 1 | 11 Participants |
Secondary
Overall Survival
Overall survival will be defined as the time from start of treatment until death from any cause and will be estimated using Kaplan-Meier methods and reported as a survival probability. Patients that are alive at the time of data analysis will be censored at the date of known survival status.
Time frame: From start of treatment up to 5 years
Population: 8 Patients were not included due to the following reasons: progressive disease, patient refused further treatment (withdrawal of consent for further treatment), toxicity. This was due to data having either missing time points or cycle 1 or Cycle 1: follow up missing from the dataset at the time of the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Regorafenib) | Overall Survival | 14.06 months |
Secondary
Progression-Free Survival (PFS) at 3 and 6 Months
The progression-free survival (PFS) at 3 and 6 months will be defined as the number of patients with progression absent at 3 months and 6 months divided by the total number of evaluable study patients. This will be measured from start of treatment until time of progression or death, whichever occurs first and will be estimated using Kaplan-Meier methods and reported as a survival probability. Progression will be evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in RECIST v 1.1. Progression will be defined as: Progressive disease (PD): \> 20% increase in the sum diameters of target lesions, taking as reference the smallest sum diameters while on study. The sum diameters must also demonstrate an absolute increase of 5 mm. The appearance of one or more new lesions also qualifies as PD.
Time frame: Assessed at 3 months and 6 months
Population: 8 Patients were not included due to the following reasons: progressive disease, patient refused further treatment (withdrawal of consent for further treatment), toxicity. This was due to data having either missing time points or cycle 1 or Cycle 1: follow up missing from the dataset at the time of the analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Regorafenib) | Progression-Free Survival (PFS) at 3 and 6 Months | 3 months | 56.52 percentage patients alive |
| Treatment (Regorafenib) | Progression-Free Survival (PFS) at 3 and 6 Months | 6 months | 47.83 percentage patients alive |
Secondary
Rate of Tumor Control
Imaging will be used at baseline then after every 2 cycles while on treatment to measure tumor size and response to treatment, the data collected from all patients on study will be used to calculate the rate and duration of tumor control. Response will be evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in RECIST v 1.1. Response and stable disease will be defined as the following: Complete response (CR): Disappearance of all target lesions Partial response (PR): \> 30% decrease in the baseline sum diameters of target lesions Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study
Time frame: At baseline and after every 2 cycles, up to 12 cycles where one cycle is 28 days
Population: 8 Patients were not included due to the following reasons: progressive disease, patient refused further treatment (withdrawal of consent for further treatment), toxicity. This was due to data having either missing time points or cycle 1 or Cycle 1: follow up missing from the dataset at the time of the analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Regorafenib) | Rate of Tumor Control | Complete Response | 2 patients |
| Treatment (Regorafenib) | Rate of Tumor Control | Partial Response | 2 patients |
| Treatment (Regorafenib) | Rate of Tumor Control | Stable Disease | 9 patients |
Secondary
Response Rate
Imaging (such as a CT scan) will be done at baseline (within 4 weeks before the first dose) then after every 2 cycles while on treatment for tumor response evaluation. Response will be evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in RECIST v 1.1. Best response of each patient will be used and responses will be defined as the following: Complete response (CR): Disappearance of all target lesions Partial response (PR): \> 30% decrease in the baseline sum diameters of target lesions
Time frame: At baseline and after every 2 cycles, up to 12 cycles where one cycle is 28 days
Population: 8 Patients were not included due to the following reasons: progressive disease, patient refused further treatment (withdrawal of consent for further treatment), toxicity. This was due to data having either missing time points or cycle 1 or Cycle 1: follow up missing from the dataset at the time of the analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Regorafenib) | Response Rate | Complete Response | 2 participants |
| Treatment (Regorafenib) | Response Rate | Partial Response | 2 participants |